Latest balloon catheter Stories

HUDSON, N.H., May 3, 2013 /PRNewswire/ -- Atrium Medical Corporation, a business unit of MAQUET Cardiovascular, today announced the 1-year results of the INFUSE-AMI (Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. Dr. Gregg Stone, the principle investigator, presented the exciting findings at the 62(nd) Annual American College of Cardiology Conference in San Francisco, CA. INFUSE-AMI's primary endpoint was reduction in infarct size...

SAUSALITO, Calif., Nov. 19, 2012 /PRNewswire/ -- Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin(TM) Smart Catheter technology...

LAGUNA HILLS, Calif., Oct. 22, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami. On October 25, Dr. Eric Wyffels of the...

LAGUNA HILLS, Calif., Oct. 2, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. Vessix was chosen as one of the Fierce 15 based, in part, on the innovation, creativity and promise of the Vessix V2 Renal...

NATICK, Mass., Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge(TM) Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in...

PLEASANTON, Calif., July 16 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its unique Glider(TM) PTCA balloon catheter. Glider(TM) is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 - 3.5mm and in lengths from 4mm to 20mm. "Glider(TM) provides interventional cardiologists with an entirely new degree of control during the treatment of complex side...

PLEASANTON, Calif., May 23, 2012 /PRNewswire/ -- TriReme Medical, Inc. (TMI) today announced approval by the U.S. Food and Drug Administration (FDA) of the Glider(TM) PTCA Catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion. Glider(TM) is the world's only torqueable PTCA balloon catheter. Combined with its state of the art tip technology, Glider(TM) is designed to perform, even in the most challenging conditions....

MAHWAH, N.J., May 14, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new MEGA 7.5Fr. 30cc and 40cc intra-aortic balloon (IAB) catheters. These new, larger volume catheters will allow clinicians to provide patients with greater hemodynamic support, regardless of their height. "The MEGA family of catheters represents a...

LAGUNA HILLS, Calif., May 1, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System(TM) for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to...

NATICK, Mass., April 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge(TM) PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability to address challenging lesions. The company plans to launch the product immediately in CE Mark countries in both Monorail® and Over-The-Wire (OTW) options. Commercial...